WHO Issues Emergency Use Listing to Novavax-Serum Institute's COVID-19 Vaccine

The World Health Organization issued an emergency use listing to Covovax, Serum Institute of India's version of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine.

• The vaccine, named Covovax, is produced by the Serum Institute of India and is part of the COVAX facility portfolio.

• It requires two doses and is stable at 2 to 8 °C refrigerated temperatures.

• Related Link: Serum Institute's CEO Expects To Launch Novavax Vaccine For Kids In Six Months: Reuters.

• The vaccine uses a novel platform and is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.

• The originator product produced by Novavax, named Nuvaxovid, is currently under assessment by the European Medicines Agency (EMA).

• WHO will complete its assessment of this vaccine once the EMA has issued its recommendation.

• Price Action: NVAX shares are up 11% at $216.32 during the market session on the last check Friday.

See more from Benzinga

• Novavax Files For Approval Of Its COVID-19 Vaccine In Japan

• Serum Institute's CEO Expects To Launch Novavax Vaccine For Kids In Six Months: Reuters

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.